As seen in Drug Discovery & Development

New research on the PI3K pathway is leading to a better understanding of its role in cancers, particularly breast cancer and non-small-cell lung cancer. To more precisely determine how the PI3K signal transduction pathway is activated, Quintiles researchers have adopted various biomarkers and methodologies and are currently developing other technologies to assess multiple PI3K mutations. The goal: a multifaceted testing solution for oncology clinical development, that will guide predictions of response or resistance to therapies and ultimately improved treatment outcomes.